0000899243-22-037475.txt : 20221202 0000899243-22-037475.hdr.sgml : 20221202 20221202174856 ACCESSION NUMBER: 0000899243-22-037475 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221130 FILED AS OF DATE: 20221202 DATE AS OF CHANGE: 20221202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harrison Seth Loring CENTRAL INDEX KEY: 0001404955 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 221443196 MAIL ADDRESS: STREET 1: 230 PARK AVENUE, SUITE 2800 CITY: NEW YORK STATE: NY ZIP: 10169 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-30 0 0001744659 Akero Therapeutics, Inc. AKRO 0001404955 Harrison Seth Loring C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2022-11-30 4 S 0 6322 46.4355 D 141080 D Common Stock 2022-11-30 4 S 0 4779 47.6044 D 136301 D Common Stock 2022-11-30 4 S 0 6851 46.4355 D 153242 I See Footnote Common Stock 2022-11-30 4 S 0 5179 47.6044 D 148063 I See Footnote The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.28 to $47.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.29 to $47.93, inclusive. Represents shares held directly by Les Pommes, LLC, a family limited liability company for which the reporting person is the manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. /s/ Jonathan Young, attorney-in-fact 2022-12-02